The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss

Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss

March 10, 2021 • By Matthew Phelan

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab vs. oral alendronate, a small clinical trial shows.

You Might Also Like
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
  • Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World
Explore This Issue
April 2021

The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Denosumab may be considered as an alternative first-line therapy in higher risk patients using chronic glucocorticoids and in those who are contraindicated for or intolerant to” bisphosphonates, Dr. Chi Chiu Mok of Tuen Mun Hospital and colleagues write.

“The strength of our study is that this is not a commercially sponsored trial,” he tells Reuters Health by email. “The weakness, of course, is the relatively short follow-up time and the sample size from one center. Yet, we feel that it is important to have data in purely Asian patients.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Previous randomized controlled trials have shown denosumab to be superior to bisphosphonates in postmenopausal women, but there is a lack of data from long-term steroid users, particularly Asians, the researchers note.

To investigate, they recruited 139 patients who were receiving long-term prednisolone therapy (at least 2.5 mg/day for at least one year) to a year-long study. All of the patients, 96% of whom were women, were being treated for autoimmune inflammatory diseases as outpatients at Tuen Mun clinics.

Half were randomly assigned to receive denosumab injections (60 mg every six months) and half to receive oral alendronate (70 mg per week). The alendronate group had a higher number of chronic smokers, but there were no other significant differences between the groups.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The patients’ mean age was 50 years and their mean BMI was 23 kg/m2. At the start of the study, they had been taking prednisolone for a mean of 107 months at a mean daily dose of 5.1 mg.

The majority of the patients (59%) had never been previously treated for osteoporosis, whereas the rest had been taking oral bisphosphonates. With one exception, all the patients were ethnic Chinese.

After 12 months, gains in bone-mineral density (BMD) at the lumbar spine favored denosumab-treated patients (3.5% vs. 2.5%), with significantly higher BMD after adjusting for baseline BMD values, age, sex, osteoporosis risk factors and cumulative prednisolone doses received in one year (P=0.045).

Differences in hip and femoral-neck BMD were not statistically significant between the groups.

Denosumab-treated patients showed significantly greater drops in the levels of serum P1NP (53% vs. 22%) and beta-CTX (57% vs. 5.3%) at the 12-month point.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: alendronate, bone loss, bone mineral density (BMD), denosumab, GlucocorticoidsIssue: April 2021

You Might Also Like:
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
  • Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.